4.510USD+2.50%Mkt Cap: 234.19M USDP/E: —Last update: 2026-05-22
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap234.19M USD
Enterprise Value131.39M USD
Revenue (TTM)3.93M USD
Gross Profit-34.27M USD
Net Income (TTM)-80.40M USD
Revenue/Share0.0990 USD
Last Price4.510 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.01
PEG—
EV/EBITDA-2.61
EV/Revenue33.40
P/S58.08
P/B7.39
EPS (TTM)-2.35
EPS (Forward)-0.73
52W Range
1.30550% of range7.750
52W High7.750 USD
52W Low1.305 USD
Profitability
Gross Margin0.00%
Oper. Margin-1010.12%
EBITDA Margin0.00%
Profit Margin-2298.54%
ROE-168.55%
ROA-68.25%
Growth
Revenue Growth50.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M USD
CapEx (TTM)279.00K USD
FCF Margin-366.45%
FCF Yield-6.16%
Net Debt-97.09M USD
Net Debt/EBITDA1.93
Balance Sheet
Debt/Equity0.04
Current Ratio6.15
Quick Ratio5.97
Book Value/Sh0.5950 USD
Cash/Share1.911 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.200 USD
Target Range5.000 USD – 12.00 USD
# Analysts5
Ownership
Shares Out.51.93M
Float29.22M
Insiders13.07%
Institutions86.62%
Short Interest
Short Ratio6.0d
Short % Float1.28%
Short % Out.0.87%
Shares Short450.46K
Short (prev mo.)414.24K
Technical
SMA 504.537 (-0.6%)
SMA 2003.995 (+12.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)77.80K
Avg Vol (10d)89.26K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—